Jump to content

Draft:David John Porteus

From Wikipedia, the free encyclopedia
  • Comment: Note to reviewers: if/when accepted, the article should be placed at David John Porteous (= correct spelling of 'Porteous'). -- DoubleGrazing (talk) 19:11, 20 January 2025 (UTC)
  • Comment: Probably notable, but too much unreferenced information, esp. for an article on a living person (WP:BLP). DoubleGrazing (talk) 15:57, 20 January 2025 (UTC)

David John Porteous OBE (born 3 July 1954), is a Scottish geneticist known for work in the field of genetics. He is Professor Emeritus of Genetics at The University of Edinburgh.[1]

Education

[edit]

Porteous attended the Aberdeen Grammar School before attending the University of Edinburgh as an undergraduate (1971–1975) specialising in genetics and a PhD (1975–1978) in metabolic control analysis (now known as systems biology), under the supervision of Dr Henrik Kacser.

Research

[edit]

Porteous has contributed to research projects in cystic fibrosis gene therapy[2][3][4] and the first clinical trial of gene therapy in Scotland.[5] In 2001, his group joined with researchers at Imperial College London and University of Oxford to form the UK Cystic Fibrosis Gene Therapy Consortium.[6] and psychiatric genetics.[7] and Andrew M. McIntosh, he identified genetic risk factors for major mental illness, most notably DISC1.[8]

Awards

[edit]

Prizes

[edit]
  • 2004: Chancellor's Award for Research, University of Edinburgh[12]
  • 2015: Fondation IPSEN Neuronal Plasticity Prize[13]

References

[edit]
  1. ^ "Professor David Porteous". 20 January 2025.
  2. ^ Dorin, JR; Dickinson, P; Alton, EW; Smith, SN; Geddes, DM; Stevenson, BJ; Wimber, KL; Fleming, S; Clarke, AR; Hooper, ML; Anderson, L; Beddington, RSP; Porteous, DJ (1992). "Cystic fibrosis in the mouse by targeted insertional mutagenesis". Nature. 359 (6392): 211–215. Bibcode:1992Natur.359..211D. doi:10.1038/359211a0. PMID 1382232.
  3. ^ Alton, EWFW; Middleton, PG; Caplen, PK; Smith, SN; Steel, DM; Munkonge, BJ; Jeffery, PK; Geddes, SL; Hart, SL; Williamson, R; Fasold, KI; Miller, AD; Dickinson, P; Stevenson, BJ; McLachlan, G; Dorin, JR; Porteous, DJ (1993). "Non–invasive liposome–mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice". Nature Genetics. 3 (2): 135–142. doi:10.1038/ng1093-135. PMID 7504552.
  4. ^ Caplen, NJ; Alton, EWFW; Middleton, PG; Dorin, J; Stevenson, BJ; Gao, X; Durham, SR; Jeffery, PK; Hodson, ME; Coutelle, C; Huang, L; Porteous, DJ; Williamson, R; Geddes, DM (1995). "Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis". Nature Medicine. 1 (1): 39–46. doi:10.1038/nm0195-39. PMID 7584951.
  5. ^ Porteous, DJ; Dorin, JR; Davidson-Smith, H; Davidson, H; Stevenson, BJ; Carothers, AD; Wallace, WAH; Moralee, S; Hoenes, C; Kallmeyer, G; Michaelis, U; Naujoks, DK; Ho, L-P; Samways, JM; Imrie, M; Greening, AP; Innes, JA (1997). "Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis". Gene Therapy. 4 (3): 210–218. doi:10.1038/sj.gt.3300390. PMID 9135734.
  6. ^ Alton, EWFW; Armstrong, DK; Ashby-D, H; Bayfield, KJ; Bilton, D; Bloomfield, EV; Boyd, AC; Brand, J; Buchan, R; Calcedo, R; Carvelli, P; Chan, M; Cheng, SH; Collie, DDS; Cunningham, S; Davidson, HE; Davies, JC; Davies; Davies, LA; Dewar, MH; Doherty, A; Donovan, J; Dwyer, N; Elgmati, HI; Featherstone, RF; Gavino, J; Dea-Sorli, S; Geddes, DM; Gibson, JSR; Gill, DR; Greening, AP; Griesenbach, U; Hansell, DM; Harman, K; Higgins, TE; Hodges, SL; Hyde, SC; Hyndman, L; Innes, JA; Jacob, J; Jones, N; Keogh, BF; Limberis, MP; MacLean, AW; Manvell, MC; MCormick, D; McGovern, M; McLachlan, G; Meng, C; Monterp, MA; Milligan, H; Moyce, LJ; Murray, GD; Nicholson, AG; Osadolor, T; Parra-Leiton, J; Porteous, DJ; Pringle, IA; Punch, EK; Pytel, KM; Quittner, AL; Rivellini, G; Saunders, CJ; Scheule, RK; Sheard, S; Simmonds, NJ; Smith, K; Smith, SN; Soussi, N; Soussi, S; Spearing, EJ; Stevenson, BJ; Summer-Jones, SG; Turkkila, M; Ureta, RP; Waller, MD; Wasowicz, MY; Wilson, JM; Wolstenholme-Hogg, P; UK Cystic Fibrosis Gene Therapy Consortium, UK (2015). "Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial". Lancet Respiratory Medicine. 3 (9): 684–691. doi:10.1038/sj.gt.3300390. PMC 4673100. PMID 26149841. {{cite journal}}: Unknown parameter |DUPLICATE_first17= ignored (help); Unknown parameter |DUPLICATE_first44= ignored (help); Unknown parameter |DUPLICATE_last44= ignored (help)
  7. ^ "Douglas Blackwood". 20 January 2025.
  8. ^ Millar, JK; Pickard, BS; Mackie, S; James, R; Christie, S; Buchanan, SR; Malloy, MP; Chubb, JE; Huston, E; Baillie, GS; Thomson, PA; Hill, EV; Brandon, NJ; Rain, J-C; Carmago, LM; Whiting, PJ; Houslay, MD; Blackwood, DHR; Muir, WJ; Porteous, DJ (1993). "DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling". Science. 310 (5751): 135–142. doi:10.1126/science.1112915. PMID 16293762.
  9. ^ "David Porteous". 20 January 2025.
  10. ^ "David Porteous". 20 January 2025.
  11. ^ "David Porteous OBE". 20 January 2025.
  12. ^ "Chancellor's Award Winner". 20 January 2025.
  13. ^ "Neuronal Plasticity Prize". 20 January 2025.
Retrieved from "http://en.wiki.x.io/w/index.php?title=Draft:David_John_Porteus&oldid=1270689910"